Neurol. praxi. 2025;26(6):520-526 | DOI: 10.36290/neu.2025.045

NMOSD as a comorbidity of clinically silent Sjögren's syndrome

MUDr. Tereza Strnadová^{1, 2}, MUDr. Dalibor Zimek^{1, 2}

¹ Neurologická klinika a Centrum klinických neurověd Lékařské fakulty Univerzity Palackého v Olomouci

² Fakultní nemocnice Olomouc

NMOSD (Neuromyelitis optica spectrum disorders) is a group of rare inflammatory autoimmune demyelinating diseases affecting most commonly the optic nerve, brainstem and spinal cord. During diagnostic process is necessary to rule out multiple sclerosis and myelin oligodendrocyte glycoprotein antibody-positive disease (MOGAD). NMOSD and MOGAD are still quite new diagnostic entities. Without treatment, NMOSD has a high risk of relapse and the possibility of permanent disability, especially in young people and those of working age, which is multiplied by its comorbidities. Part of the diagnostic process involves ruling out other neurological causes of the patient's current symptoms and accurately identifying the disease so that targeted therapy can be set up. The aim of this article is to highlight the fact that NMOSD can manifest itself at an older age and can also accompany systemic rheumatological diseases.

Keywords: NMOSD, neuromyelitis optica, Sjögren's syndrome, LETM, tocilizumab.

Received: February 24, 2025; Revised: April 30, 2025; Accepted: May 19, 2025; Prepublished online: May 19, 2025; Published: December 15, 2025  Show citation